ella

About Ella Korets-Smith

This author has not yet filled in any details.
So far Ella Korets-Smith has created 19 blog entries.

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES COLLABORATION WITH NORIA PHARMACEUTICALS INC.

2018-07-19T11:15:51+00:00

Vancouver, British Columbia / July 17, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to announce the Collaboration  of APC with Noria Pharmaceuticals Inc. in the rapidly growing field of antibody radioisotope conjugates. APC will test its proprietary, site-selective, linker technology with Noria’s proprietary MacroPa radioisotope chelation [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES COLLABORATION WITH NORIA PHARMACEUTICALS INC.2018-07-19T11:15:51+00:00

ADVANCED PROTEOME THERAPEUTICS ADVANCES ITS TECHNOLOGICAL CAPABILITY

2018-06-27T11:25:17+00:00

Vancouver, British Columbia / June 18, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), is pleased to report continuing progress on its efforts to develop superior antibody drug conjugates (ADCs). Proceeding from cytotoxicity studies to the next phase of testing in animals necessitates scaling up processes by a significant [...]

ADVANCED PROTEOME THERAPEUTICS ADVANCES ITS TECHNOLOGICAL CAPABILITY2018-06-27T11:25:17+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF BILL DICKIE AS CHIEF EXECUTIVE OFFICER AND DIRECTOR

2018-06-07T14:01:35+00:00

VANCOUVER, British Columbia, June 06, 2018 (GLOBE NEWSWIRE) -- Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV:APC) (FSE:0E8) is pleased to announce the appointment of Mr. Bill Dickie as Chief Executive Officer, President and Director of the company, effective June 6, 2018. Mr. Dickie brings with him more than 30 years of exceptionally qualified experience in [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF BILL DICKIE AS CHIEF EXECUTIVE OFFICER AND DIRECTOR2018-06-07T14:01:35+00:00

ADVANCED PROTEOME THERAPEUTICS UPDATES ITS ACTIVITIES DURING THE 3RD QUARTER, FY 2018

2018-05-08T09:47:05+00:00

Vancouver, British Columbia / May 1, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to provide an update of progress during the third quarter, FY 2018. The Company, in its pursuit of commercial success is vigourously applying innovative core principles ((Marketwired - January 31, 2018) to advance [...]

ADVANCED PROTEOME THERAPEUTICS UPDATES ITS ACTIVITIES DURING THE 3RD QUARTER, FY 20182018-05-08T09:47:05+00:00

ADVANCED PROTEOME ANNOUNCES APPOINTMENT OF SCIENTIFIC ADVISORY BOARD MEMBERS

2018-04-29T21:59:00+00:00

Vancouver, British Columbia / April 24, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce the appointments of two new members to its Scientific Advisory Board (SAB):  Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital Cancer Center (MGHCC), Harvard Medical [...]

ADVANCED PROTEOME ANNOUNCES APPOINTMENT OF SCIENTIFIC ADVISORY BOARD MEMBERS2018-04-29T21:59:00+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF NEW BOARD MEMBERS

2018-04-29T21:56:42+00:00

Vancouver, British Columbia / April 16, 2018– Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce the appointments of Dr. John R. Garrett and Paul Woodward to its Board of Directors. Dr. Garrett is a Principal of John Garrett & Partners with a practice focusing on early stage US and [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES APPOINTMENT OF NEW BOARD MEMBERS2018-04-29T21:56:42+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES CLOSING OF SECOND TRANCHE OF AN OVER-SUBSCRIBED NON-BROKERED PRIVATE PLACEMENT

2018-03-13T09:17:12+00:00

Vancouver, British Columbia / March 12, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news release of March 5, 2018 and, due to high demand, it has closed a second tranche of its over-subscribed private placement (the “Private Placement”) raising additional [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES CLOSING OF SECOND TRANCHE OF AN OVER-SUBSCRIBED NON-BROKERED PRIVATE PLACEMENT2018-03-13T09:17:12+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES INCREASE TO NON-BROKERED PRIVATE PLACEMENT

2018-03-08T09:07:26+00:00

Vancouver, British Columbia / March 7, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, further to its news releases of February 21, 2018 and March 5, 2018, it has increased the previously announced private placement of units from 8,500,000 units at $0.08 to 11,500,000 [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES INCREASE TO NON-BROKERED PRIVATE PLACEMENT2018-03-08T09:07:26+00:00

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES CLOSING OF FIRST TRANCHE OF AN OVER-SUBSCRIBED NON-BROKERED PRIVATE PLACEMENT

2018-03-08T09:08:18+00:00

Vancouver, British Columbia / March 5, 2018 – Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8) is pleased to announce that, due to high demand, it has closed the first tranche of its over-subscribed private placement (the “Private Placement”) raising gross proceeds of $824,000 by the issuance of 10,300,000 units (the [...]

ADVANCED PROTEOME THERAPEUTICS ANNOUNCES CLOSING OF FIRST TRANCHE OF AN OVER-SUBSCRIBED NON-BROKERED PRIVATE PLACEMENT2018-03-08T09:08:18+00:00

ADVANCED PROTEOME THERAPEUTICS AND IMMUNOBIOCHEM CORPORATION ENTER INTO A COLLABORTATION AND OPTION AGREEMENT

2018-02-17T09:31:18+00:00

Feb 7, 2018 (Vancouver, BC and Toronto, ON): Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates.  The companies will evaluate the prospect of combining ImmunoBiochem’s proprietary antibody and APC’s site-selective conjugation technology to produce ADCs [...]

ADVANCED PROTEOME THERAPEUTICS AND IMMUNOBIOCHEM CORPORATION ENTER INTO A COLLABORTATION AND OPTION AGREEMENT2018-02-17T09:31:18+00:00